Back

The connoisseurs

Trialist

Current states

Has the expertise to understand the differences between toxins, but Continue to use Botox alongside Dysport® as I like to have multiple ‘tools’ at my disposal

Desired states

Believe IPSEN provide exceptional partnership to injectors and as a result of the learning opportunities provided, Motivated to put Dysport® to the test across a broader range of patient types

Communication objectives

  1. Convince HCPs of symptom control benefits of Dysport®, especially in complex cases
  2. Enhance relationship with IPSEN by offering opportunities to learn and connect with peers
target

Messaging should be science-led, offering technical details and statements that challenge the HCP.

Communication objective associated: Demonstrate the added value of Dysport® with strong data which makes it the toxin of choice

  1. More patients can access treatment thanks to Dysport®’s broad reimbursement coverage in spasticity which enables clinicians to treat a wider spectrum of patients including complex case

  2. Cost-effective treatment supports continuity of care and goal achievement without compromise.

Key supportive reference:

Key material:

  • CLM presentation
  • Discover Dysport®

Digital material for follow up:

  • VAE reimbursement

Communication objective associated: Demonstrate the added value of Dysport® with strong data which makes it the toxin of choice

  1. Dysport® delivers sustained improvements in muscle tone and range of motion, cycle after cycle.

  2. Functional gain such as increased walking speed and active movement are consistently achieved and maintained across multiple treatment cycles.

  3. Cycle-by-cycle data (ULIS III, AboLiSh) confirm cumulative goal attainment and measurable progress in complex spasticity cases.

Key supportive study :

  • Upper limb: Gracies J, et al. Muscle Nerve. 2018;57(2):245-254, ULIS-III: Turner-Stokes L, et al. J Rehabil Med. 2021;53(1):jrm00133
  • Lower limb: Gracies J, et al. Neurology. 2017;89(22):2245-2253, AboLiSh: Esquenazi A, et al. Arch Phys Med Rehabil. 2024 

Key material:

  • CLM presentation
  • AboLiSh infographic
  • ULIS-III infographic

Digital material for follow up:

  • GAS VAE (to come)
  • Goal seeting podcast Jacinto 
  • Goal seeting video Jacinto 

Communication objective associated:  Demonstrate the added value of Dysport® with strong data which makes it the toxin of choice

  1. The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered

  2. Phase 3 trials confirm Dysport® delivers sustained symptom control, with statistically significant intervals between reinjections.

  3. Comparative studies show Dysport® achieves longer-lasting control versus other BoNT-As in routine clinical practice.

Main key supportive study :

  • Upper limb: Gracies J, et al. Muscle Nerve. 2018;57(2):245-254 
  • Lower limb: Gracies J, et al. Neurology. 2017;89(22):2245-2253

Key material:

  • CLM presentation

Digital material for follow up:

  • Esquenazi webinar 
  • Jacinto reflection 
  • VAE to Ipsen Academy (to come)
  • VAE on duration of response (to come)

Communication objective associated: Demonstrate the added value of Dysport® with strong data which makes it the toxin of choice

  1. Dysport® delivers the highest active neurotoxin content per licensed dose among BoNT-As, enabling tailored treatment strategies

  2. 62% response rate for upper limb and 83% for lower limb as primary treatment targets, demonstrating efficacy across muscle groups.

  3. Dysport® has a dose-response effect recommended doses for upper and lower limb muscles are supported by robust clinical evidence.

  4. The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered

Main key supportive study :

  • Field M, et al. Toxins. 2018;10:535
  • Gracies J, et al. J Neurol Phys Ther. 2021;45:203-213. 

Key material:

  • CLM presentation
  • Dilution table
  • Reconstitution / Dosing leaflet
  • Muscle map

Digital material for follow up:

  • VAE reconstitution (to come)
  • VAE dosing (to come)
  • VAE Dysport in x points (to come)

Communication objective associated: Demonstrate the added value of Dysport® with strong data which makes it the toxin of choice

  1. With 30 years of experience, Dysport® has a well-characterised safety profile at approved doses
  2. Dysport® offers a consistent safety profile across both low and high doses

Main key supportive study :

  • Upper limb: Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb: Gracies J, et al. Neurology. 2017;89(22):2245-2253

Key material:

  • CLM presentation

Communication objective associated: Enhance relationship with IPSEN by offering opportunities to learn and connect with peers

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early
    return of debilitating symptoms    3–7
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Key material

  • CLM presentation
  • Dosing app
  • Ixcellence website

Digital material for follow up

  • Invitation to (inter)national training
  • Dosing app guide (to come)